Active, not recruitingPhase 3NCT05624749
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
Studying Autosomal systemic lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- ianalumab(drug)
- Enrollment
- 288 enrolled
- Eligibility
- 12-100 years · All sexes
- Timeline
- 2023 – 2029
Study locations (30)
- Pinnacle Research Group LLC, Anniston, Alabama, United States
- Advanced Medical Research, La Palma, California, United States
- University of California LA, Los Angeles, California, United States
- Homestead Assoc In Research Inc, Homestead, Florida, United States
- IRIS Research and Development, Plantation, Florida, United States
- Emory University, Atlanta, Georgia, United States
- Willow Rheumatology Wellness, Willowbrook, Illinois, United States
- Bluegrass Community Research Inc, Lexington, Kentucky, United States
- Accurate Clinical Research, Lake Charles, Louisiana, United States
- UMC New Orleans, New Orleans, Louisiana, United States
- University Of Maryland, Baltimore, Maryland, United States
- Ahmed Arif Medical Research Center, Grand Blanc, Michigan, United States
- Washington Univ School Of Medicine, St Louis, Missouri, United States
- Thomas Jefferson University, Philadelphia, Pennsylvania, United States
- West Tennessee Research Institute, Jackson, Tennessee, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05624749 on ClinicalTrials.govOther trials for Autosomal systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07447986To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus ErythematosusHangzhou Sumgen Biotech Co., Ltd.
- RECRUITINGPHASE1NCT07363590A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)Merck Sharp & Dohme LLC
- RECRUITINGPHASE3NCT07201129A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular TreatmentViatris Innovation GmbH
- RECRUITINGPHASE1NCT07276958A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)Eli Lilly and Company
- RECRUITINGPHASE1, PHASE2NCT07348055A Study of GR1803 in Systemic Lupus ErythematosusGenrix (Shanghai) Biopharmaceutical Co., Ltd.
- RECRUITINGNCT07000110Anifrolumab Malignancy and Serious Infections StudyAstraZeneca
- RECRUITINGPHASE1NCT07318259Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLEChongqing Precision Biotech Co., Ltd
- RECRUITINGPHASE1NCT07331467Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLEChongqing Precision Biotech Co., Ltd